VGX 3200

Drug Profile

VGX 3200

Alternative Names: GHRH 1-44; GHRH-1-44-NH2; Growth Hormone-Releasing Factor 44; hpGRF 44; VGX-3200

Latest Information Update: 30 Apr 2012

Price : $50

At a glance

  • Originator Baylor College of Medicine
  • Developer Inovio Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Anaemia; Cachexia

Most Recent Events

  • 30 Apr 2012 Preclinical development is ongoing in USA
  • 14 May 2010 Inovio Biomedical is now called Inovio Pharmaceuticals
  • 02 Jun 2009 VGX Pharmaceuticals has been acquired and merged into Inovio Biomedical Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top